Pfizer expects to file for full US Food and Drug Administration approval of its Covid-19 vaccine for 16-to-85-year-olds by the end of May, the company said during its first quarter 2021 earning teleconference Tuesday. 

“While we are currently distributing our vaccine in the US under an Emergency Use Authorization (EUA), we expect to submit this month a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking full approval for our Covid-19 vaccine for individuals 16 years of age and older,” Pfizer CEO Albert Bourla said in his remarks.